Tolerance of ALL Induction Therapy in Children with Limited Resources: A Retrospective Study from a Teaching Hospital

Author:

Khanna Tanvi,Agrawal Nitika,Das Kunal,Kalra Brahma Prakash

Abstract

Introduction: Acute Lymphoblastic Leukaemia (ALL) is the most common malignancy in children. Due to the better understanding of biology, intensive multi-agent chemotherapy and improved supportive care, ALL is curable in majority of children. Induction phase is the most intense and critical phase of therapy. Aim: To examine the feasibility of high-intensity induction and its tolerance in a resource-limited setting in children with acute lymphoblastic leukaemia. Materials and Methods: This retrospective analysis was done on children admitted for ALL treatment. Data was collected for January 2016 to July 2018, regarding baseline characteristics, tolerance to induction therapy, morbidity, mortality, deviations from protocol, and induction outcomes among children with ALL treated at a tertiary care teaching hospital (Cancer Research Institute, Himalayan Institute of Medical Sciences, Dehradun, Uttrakhand, India). Confirmed cases of ALL with age upto 18 years, who took more than a week of planned induction were included in the study. Data was analysed using Chi-square and Fisher-Exact test. Results: Four-drug induction was feasible and given to 76 patients during the study period. Mean age of the group was 9.3 years. Male: female ratio was 1.3:1. Remission was achieved in 63 (82.8%) patients. Four deaths occurred, and were attributed to infection. Hyperglycaemia (4), CNS events (2), peripherally inserted central line related thrombosis (2) and pulmonary tuberculosis (1) were noted among four, two, two, and one cases, respectively. Febrile neutropenia was noted in 65 cases and seven cases required ICU care; two of them succumbed in the ICU. Baseline blood parameters, subtype of disease, protocol of treatment and age did not affect the induction outcome statistically. Conclusion: Intensive induction chemotherapy has varying complications and can be employed even in resource-limited settings with acceptable results.

Publisher

JCDR Research and Publications

Subject

Clinical Biochemistry,General Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3